Speaker illustration

undefined undefined undefined

Moderate-intensity statin plus ezetimibe combination therapy versus high-intensity statin monotherapy according to baseline LDL-C levels: a prespecified subgroup analysis of RACING Trial

Event: ESC Congress 2023

Topic: Lipid-Lowering Agents

Session: Statins, bempedoic acid and ezetimibe: novel findings

Thumbnail

ESC 365 is supported by